Red light therapy after menopause is easy to overbelieve.
It is also too studied to dismiss. A 2023 systematic review screened 554 records, included 31 LED studies, and found skin-rejuvenation signals, while also showing that outcomes vary by condition and study quality. [1]
The useful answer is the middle one: red and near-infrared light can be a modest cosmetic adjunct when the device, wavelength, dose, and schedule are real. It is not a hormone treatment, not a collagen reset, and not a substitute for diagnosing rash, pigment, photosensitivity, or suspicious lesions.
The best-fit use is wrinkles or texture, not every skin concern
Photobiomodulation is not one treatment. A 2024 JAAD review describes it as red light from 620 to 700 nm and near-infrared light from 700 to 1440 nm, delivered through sources such as low-level lasers or LEDs. The same review emphasizes that clinical effects depend on parameters such as fluence, treatment duration, and output power. [7]
That is why "red light" on the box is not enough. The evidence is limited by device, dose, outcome, and skin type.
| Goal after menopause | Evidence posture | Better first question |
|---|---|---|
| Fine lines around the eyes | Plausible adjunct if the device and protocol match studied ranges | What wavelength, dose, schedule, and outcome were tested? |
| Texture or roughness support | Plausible adjunct, but usually repeated-use and modest | Am I still using sunscreen, moisturizer, and established topicals when appropriate? |
| Melasma, brown patches, or post-inflammatory pigment | Evidence is not strong enough to make this the first step | Has pigment been diagnosed, and am I using visible-light-aware sunscreen? |
| Rosacea flushing, burning, rash, dermatitis, or contact irritation | Poor fit until diagnosed | Is inflammation or sensitivity the real problem? |
| Rough sun-damage spots or changing, bleeding, painful, or itchy lesions | Not a cosmetic-device problem | Does this need dermatology evaluation before any home device? |
| Expecting menopause reversal or collagen restoration | Poor fit for the claim | Is the advertised promise larger than the trial result? |
For pigment-first concerns, start with Melasma After Menopause Treatment Options. For rough or changing sun-damage spots, see Actinic Keratosis After Menopause: Rough Spots, Sun Damage, and Red Flags.
What wrinkle trials actually found
The most useful trials are not category claims. They are specific protocols.
In one split-face randomized clinical trial, 137 women ages 40 to 65 with photoaging received 10 sessions over 4 weeks. Red 660 nm and amber 590 nm photobiomodulation used the same dose, 3.8 J/cm2, on opposite sides of the face. Periocular wrinkle volume fell 31.6% with red light and 29.9% with amber light, but hydration and viscoelasticity did not improve. [2]
That is a meaningful result and a boundary. The trial supports a periocular-wrinkle outcome under that protocol, not a general claim that any mask improves every menopause skin change.
A 2025 multicenter, randomized, double-blind, sham-controlled home-mask trial studied 60 adults ages 30 to 65 with Fitzpatrick skin types II to V. The active device combined 630 nm LED and 850 nm infrared emitting diode light. Crow's-feet scores separated from sham at 8, 12, and 16 weeks, and independent-rater improvement rates in the full analysis and per-protocol sets were 86.2% and 89.3%. [3]
Older trials point in the same direction but also show how protocol-specific the evidence is. A 2014 controlled trial enrolled 136 volunteers, treated 113 people across four light-treatment groups, kept 23 controls, and used 30 sessions; treated groups improved skin feeling, roughness, and ultrasound-assessed collagen density compared with controls. [4] A 2007 split-face study of 76 people used 830 nm, 633 nm, a combination, or sham twice weekly for 4 weeks, followed participants for 3 months, and reported wrinkle reductions up to 36% and elasticity increases up to 19% without adverse effects in the study. [5]
The number to remember is not "36%" or "31.6%" by itself. It is that the result came from a named wavelength, repeated sessions, and measured outcomes.
What FDA-cleared does and does not mean
At-home device marketing often uses regulatory language loosely.
The American Academy of Dermatology tells consumers to choose an FDA-cleared red-light device and follow its directions. It also explains the limit: "FDA-cleared" or "510(k)-cleared" indicates the device is generally considered safe or cleared through that device pathway, not that it is established to work for every advertised cosmetic claim. The American Academy of Dermatology also warns that terms like "FDA approved" or "FDA certified" are not meaningful for this kind of device marketing. [6]
Use this as the buyer filter:
| Claim on the product page | What it should mean before you trust it |
|---|---|
| FDA-cleared or 510(k)-cleared | There is a traceable clearance for that device or device type, not just a logo in an ad |
| Clinically tested | The study used the same device or a meaningfully similar wavelength, dose, and schedule |
| Red plus near-infrared | The exact wavelengths are stated, such as 630 nm and 850 nm, not just color words |
| Fast collagen results | The outcome is measured in a trial and the time frame is realistic, often weeks to months |
| Safe for all skin types | The safety data include darker skin tones or the instructions address hyperpigmentation risk |
| No eye risk | The instructions clearly state whether eye protection is required and what kind to use |
If a device does not disclose wavelength, treatment time, use frequency, eye-safety instructions, contraindications, and regulatory status, the weak point is not science. It is transparency.
Safety is favorable, but not blank-check
The American Academy of Dermatology says short-term red light therapy appears safe, with mild temporary pain or irritated skin as common side effects, while noting that long-term skin and hair effects are still not fully known. It also advises seeing a dermatologist before home use, especially to assess whether the device could worsen a photosensitive condition such as lupus, interact with photosensitizing medication, or be a poor fit for the target concern. [6]
Skin tone also matters. The American Academy of Dermatology warns that people with darker skin tones should talk with a dermatologist before at-home use because visible light sensitivity can contribute to hyperpigmentation. [6] A randomized safety study makes that caution more concrete: in two trials of high-fluence red LED exposure, no serious adverse events occurred, but dose-limiting effects appeared at lower fluence in the all-skin-types study than in the non-Hispanic Caucasian study, and the authors concluded that darker skin may be more photosensitive. [9]
A 2024 JAAD overview also describes photobiomodulation as generally well tolerated, with erythema as the most common self-limiting cutaneous adverse effect. [7] The companion JAAD review states that future clinical trials are still needed to standardize recommendations across conditions and skin types. [8]
That is the safety posture: usually low-risk when used correctly, but not diagnosis-free and not skin-tone-neutral by assumption.
Who this fits, and who should avoid it
Red light therapy may fit if your main goal is fine-line or texture support, you can commit to repeated sessions, you have no suspicious lesions or active rash in the treatment area, the device has clear safety instructions, and you understand that the outcome is likely modest.
It is a weaker fit if your real problem is melasma, acne, rosacea, dermatitis, burning, scaling, a new lesion, a rough sun-damage spot, hair loss, or medication-related photosensitivity. Those are not all solved by the same light.
It should be avoided or reviewed first if you have a photosensitive condition, take medication that increases light sensitivity, have eye disease or cannot follow eye-protection instructions, have a history of pigment worsening from visible light, or are trying to treat a changing, bleeding, painful, crusting, or nonhealing spot.
For wrinkle-focused topical decisions, see Retinol vs Tretinoin After Menopause: Photoaging, Irritation, and Evidence. For baseline prevention, see Sunscreen After Menopause: Photoaging, UVA, SPF, and Daily Use.
What to ask your clinician
- Is my target problem fine lines, texture, pigment, redness, dryness, acne, rosacea, dermatitis, hair loss, or a lesion?
- Does the treatment area need an exam before a home device, especially if there is a changing, bleeding, painful, rough, or nonhealing spot?
- Do I have a photosensitive condition, a photosensitizing medication, darker-skin hyperpigmentation risk, or eye-safety reason to avoid the device?
- Does this device disclose wavelength, irradiance or fluence, session length, frequency, eye protection, contraindications, and FDA clearance?
- How long should I try it before deciding it is not worth the time or money?
- Which basics should continue in parallel: sunscreen, barrier care, retinoid decisions, pigment treatment, or rash treatment?
Bottom line
Red light therapy after menopause can be reasonable for fine-line and texture support if the device is transparent, the protocol is realistic, and the goal matches the evidence.
The best version of the claim is modest: repeated red or near-infrared light may improve some facial-aging measures in some trials.
The worst version of the claim is a device that treats "menopause skin" as a single problem. If the issue is pigment, rash, burning, photosensitivity, actinic damage, a changing lesion, or eye safety, start with diagnosis and safety before buying the mask.
Related reading: retinol vs tretinoin after menopause, sunscreen after menopause, prescription skin care after menopause, and melasma after menopause.
References
[1] Ngoc LTN, Moon JY, Lee YC. Utilization of light-emitting diodes for skin therapy: Systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2023;39(4):303-317. doi:10.1111/phpp.12841 https://pubmed.ncbi.nlm.nih.gov/36310510/
[2] Mota LR, Duarte IDS, Galache TR, et al. Photobiomodulation Reduces Periocular Wrinkle Volume by 30%: A Randomized Controlled Trial. Photobiomodul Photomed Laser Surg. 2023;41(2):48-56. doi:10.1089/photob.2022.0114 https://pubmed.ncbi.nlm.nih.gov/36780572/
[3] Park SH, Park SO, Jung JA. Clinical study to evaluate the efficacy and safety of home-used LED and IRED mask for crow's feet: A multi-center, randomized, double-blind, sham-controlled study. Medicine (Baltimore). 2025;104(7):e41596. doi:10.1097/md.0000000000041596 https://pubmed.ncbi.nlm.nih.gov/39960921/
[4] Wunsch A, Matuschka K. A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase. Photomed Laser Surg. 2014;32(2):93-100. doi:10.1089/pho.2013.3616 https://pubmed.ncbi.nlm.nih.gov/24286286/
[5] Lee SY, Park KH, Choi JW, et al. A prospective, randomized, placebo-controlled, double-blinded, and split-face clinical study on LED phototherapy for skin rejuvenation: clinical, profilometric, histologic, ultrastructural, and biochemical evaluations and comparison of three different treatment settings. J Photochem Photobiol B. 2007;88(1):51-67. doi:10.1016/j.jphotobiol.2007.04.008 https://pubmed.ncbi.nlm.nih.gov/17566756/
[6] Is red light therapy right for your skin? American Academy of Dermatology. https://www.aad.org/public/cosmetic/safety/red-light-therapy
[7] Maghfour J, Ozog DM, Mineroff J, Jagdeo J, Kohli I, Lim HW. Photobiomodulation CME part I: Overview and mechanism of action. J Am Acad Dermatol. 2024;91(5):793-802. doi:10.1016/j.jaad.2023.10.073 https://pubmed.ncbi.nlm.nih.gov/38309304/
[8] Mineroff J, Maghfour J, Ozog DM, Lim HW, Kohli I, Jagdeo J. Photobiomodulation CME part II: Clinical applications in dermatology. J Am Acad Dermatol. 2024;91(5):805-815. doi:10.1016/j.jaad.2023.10.074 https://pubmed.ncbi.nlm.nih.gov/38307144/
[9] Jagdeo J, Nguyen JK, Ho D, et al. Safety of light emitting diode-red light on human skin: Two randomized controlled trials. J Biophotonics. 2020;13(3):e201960014. doi:10.1002/jbio.201960014 https://pubmed.ncbi.nlm.nih.gov/31483941/